BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Tuesday, June 16, 2026
Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 10, 2014

View Archived Issues

Ubiquigent and University of Dundee form ubiquitin pathway compound library collaboration

Read More

Study finds new genes affected by MS-associated polymorphisms

Read More

Blaze Bioscience receives NCI funding for Tumor Paint BLZ-100 in sarcoma

Read More

VaxInnate plans study of VAX-2012Q in the elderly to begin by year-end

Read More

Promising initial phase I data for pramlintide/insulin fixed-dose combination

Read More

New ROR-gamma receptor modulators patented by Roche and Genentech

Read More

Vertex patents novel ATR inhibitors for cancer

Read More

Novel PDH kinase inhibitors patented at Japan Tobacco

Read More

A team of scientists in Taipai designs new polypeptides for C. difficile infection

Read More

Easy, safe and accurate local treatment of seborrheic keratosis lesions with BL-5010

Read More

Bristol-Myers Squibb reports new KCNA5 blockers

Read More

PIQUR plans phase I study of PQR-309 for relapsed or refractory lymphoma

Read More

Pathogen-specific PET tracer antibody-based molecular imaging of invasive Aspergillosis

Read More

Karolinska Institute awarded Knut and Alice Wallenberg Foundation grant

Read More

CytRx begins phase Ib trial evaluating combination of aldoxorubicin and gemcitabine

Read More

Novel DPP IV inhibitor discovered for the treatment of type 2 diabetes

Read More

Boston Therapeutics reports topline phase IIb data for BTI-320 in type 2 diabetes

Read More

Fusion Antibodies and ISCA Diagnostic complete humanization of Aspergillus-specific MAb

Read More

Amarantus reports data for Alzheimer's blood diagnostic LymPro Test

Read More

Topline results from the first part of a phase I/II trial of necuparanib in pancreatic cancer

Read More

ContraFect establishes collaborative research agreement with China CDC for CF-404

Read More

FDA approves Velcade for previously untreated mantle cell lymphoma

Read More

Capricor plans clinical program for cenderitide for post-acute heart failure

Read More

FDA accepts BLA for blinatumomab in acute lymphoblastic leukemia

Read More

Xoma initiates phase I trial of insulin receptor inhibitor antibody

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 15, 2026.
  • Neck exam

    Ethyreal launches to treat the underlying cause of Graves’, TED

    BioWorld
    Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
  • Illustration of Lactobacillus

    Microbiota modulates the antidepressant effects of GLP-1 analogues

    BioWorld Science
    Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...
  • Genome sequence map

    EHA 2026: With new lenses, a changing view on pediatric cancers

    BioWorld
    In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...
  • Microscopic image of chronic myeloid leukemia

    Enliven’s phase I CML data Enable phase III with BCR/ABL1 bid

    BioWorld
    Tolerability is a key factor in the appeal of Enliven Therapeutics Inc.’s ELVN-001 for previously treated chronic myeloid leukemia (CML), which yielded positive...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing